Exploring the time delay between regulatory approval and health techonology assessments (HTAs) of oncology therapies in France, Germany, England, Scotland, Canada, and Australia.

6545Background: Drugs in the USA become available from the moment of FDA approval. Access to oncology therapies outside of the USA may be delayed by regulatory and additional payer HTA processes. T...